Attached files

file filename
EX-99.2 - EXHIBIT 99.2 - AXON ENTERPRISE, INC.aaxnq419-ex992.htm
8-K - 8-K - AXON ENTERPRISE, INC.aaxnq42019-8ksharehold.htm


CONTACT:
Investor Relations
Axon Enterprise, Inc.
IR@axon.com

Axon 2019 Revenue Grows 26% to $531 Million; SaaS ARR up 49%, Setting Foundation for Continued Growth & Momentum

Scottsdale, Ariz., February 27, 2020 — Axon (Nasdaq: AAXN), the global leader in connected public safety technologies, today released the following quarterly update letter to shareholders.

Dear Shareholders,

We are pleased to report a strong finish to 2019.

Revenue grew 26% to $531 million for the year, driven by demand for our latest generation camera, Axon Body 3, the cloud-connected TASER 7, and our cloud software.

Bottom line performance reflects our ability to scale manufacturing of TASER 7, continued growth of higher margin Axon Cloud revenue (up 41% for the full year), and cost control discipline. While net income was affected by catch-up stock compensation expense, we delivered a record $88 million in adjusted EBITDA for the full year, up 43%, and Q4 2019 adjusted EBITDA more than tripled to $38 million, reflecting a 22% margin.

The successful launch of Axon Body 3 drove record Q4 2019 sales of $172 million, up 50%, and holds tremendous strategic value. Customers are enthusiastic about better core performance and situational awareness features such as live-video streaming and real-time alerts. With LTE connectivity, GPS and a more powerful CPU for edge-AI processing, Axon Body 3 is designed to improve officer performance and drive adoption of SaaS features. Importantly, this is expected to fuel continued growth in annual recurring SaaS revenue. Axon Body 3’s communications capabilities also pave the way for adoption of the emergency dispatch solution we are bringing to market this year.

Our strategic focus on driving recurring cash flow and building a self-reinforcing SaaS-centric business is working. For example, in 2019:
We achieved $161 million in annual recurring SaaS revenue, up 49% over 2018;
71% of our full-year revenue was in recurring contracts, up from 55% in 2018 and 46% in 2017;
More than 100 agencies adopted Officer Safety Plan 7, which carries per-officer-per-month pricing of $149 to $229 and created a pipeline of customers that have gained access to Axon Records;
More than 70% of Officer Safety Plan 7 users are on the top-tier 7+ plan; and
More than 550 agencies adopted the cloud-connected TASER 7, with 80% of those selecting our highest value plans.

We continue to see customer enthusiasm for Axon Records, which underscores the effectiveness of our go-to-market strategy. We’ve made it attractive for agencies to start using Records by including it as a built-in benefit to our highest tier Officer Safety Plan — and some agencies will be able to fund the majority of their upgrade to that tier with savings from transitioning their legacy records management system to Axon Records.






Our strategic priorities in 2020 include continuing to execute in our core market, while accelerating our path-to-market in new product categories such as de-escalation and communications, and expanding to new customer categories. This will position us to achieve a higher level of annual recurring SaaS revenue over the long term. Specifically:

1.
We are accelerating our R&D investments in developing real-time command-and-control software for public safety, which represents a $2 billion rapidly growing market. Axon’s cloud-based software will be designed to empower everyone involved in incident response: dispatchers, call takers, command staff, patrol officers, firefighters and medical personnel. We intend to fundamentally improve the workflow that the industry refers to as Computer Aided Dispatch, or CAD — enabling entire agencies to respond as one team to get the right people with the right information to the right place at the right time. We expect to be live by mid-year with our first paying customer.

2.
We see a major opportunity in the corrections and federal law enforcement channels. In Q4 2019, Axon won a Department of Justice contract to equip Bureau of Alcohol, Tobacco, Firearms and Explosives officers with body cameras. This contract vehicle will also allow other federal law enforcement agencies to join the Axon network. We are now proud to support both the US Forest Service’s adoption of body cameras and TASER devices, and the DOJ’s new body camera pilot effort, both representing significant milestones in Axon’s federal expansion efforts. We estimate these two markets add $1.5 billion to our core municipal public safety market.

Unlocking new opportunities means Axon’s strategic growth areas have evolved and expanded into:
De-escalation: Developing tools that support public safety officers in avoiding or minimizing use of force is a key component of Axon’s mission to protect life. These tools include the cloud-connected TASER conducted energy device as well as a suite of Augmented Reality and Virtual Reality (AR/VR) training services for law enforcement, delivered through our Axon Academy training platform. To obsolete the bullet, we intend to not only develop more effective TASER devices over time but also drive training and adoption of the best practices in modern policing.
Sensors: Our digital evidence management software, Axon Evidence, supports our network of cloud-connected cameras and sensors. Axon Evidence is the world’s largest cloud-hosted data repository of law enforcement video data and other types of electronic evidence. In September 2019, we began shipping Axon Body 3, a camera with an LTE antenna and GPS chip, which supports real-time awareness.
Productivity: Our productivity suite of tools reduce time spent on paperwork. Axon Records takes a disruptive modern approach to displace legacy on-premises Records Management Systems (RMS) by putting body camera video at the heart of incident records. Axon Records includes Axon Standards, a radically simpler approach to use-of-force reporting. Another software solution in this suite, Axon Performance, helps agencies ensure that officers are adhering to agency policies, and provides analytics on the effectiveness of body-worn camera programs. And Redaction Assistant enables agencies to redact videos in a fraction of the time through the use of artificial intelligence (AI).
Communications: We are developing communication tools that support real-time situational awareness through the sharing of information across various channels, including voice, messaging, location mapping, and intelligence and evidence sharing. Products include Axon Aware, which allows agencies to know the GPS location of their officers and what those officers are experiencing through live video streaming and more; and Axon Dispatch, the emergency dispatch solution we are bringing to market this year.

By 2030, we believe:

TASER devices will be the primary means to stop a threat
AI-enabled body cameras will eliminate the majority of manual report writing
Cloud-enabled devices will be the primary means to dispatch officers in the field





Axon will be a household name by virtue of the transformative value we'll create for society and all of our stakeholders

Summary of Q4 2019 results:

Record quarterly revenue of $172 million, up 50% year over year, included $26 million of Axon Body 3 hardware shipments, and reflected a successful product launch.
Total company gross margin of 53.9% reflected a higher-than-usual mix of body camera hardware and TASER 7 cartridges, as expected. For more details, please see gross margin commentary by segment, below.
Operating expenses of $107 million included $47.5 million in stock-based compensation expenses, including $33 million of incremental “catch up” expense. Operating expenses excluding stock-based compensation declined sequentially, reflecting rigorous cost controls.
SG&A of $78 million included $40.2 million in stock-based compensation expenses, including $29.9 million in “catch up” expenses.
R&D of $29 million included $7.3 million in stock-based compensation expenses, including $2.9 million in “catch up” expenses.
These “catch up” expenses are tied to Axon’s CEO Performance Award and eXponential Stock Performance Plan (“XSPP”), for which six additional performance goals became probable of attainment during Q4 2019 due to our strengthened outlook, bringing the total number of performance goals that are statistically probable to nine.
GAAP EPS was ($0.21); Non-GAAP EPS of $0.41 excludes non-cash stock-based compensation expense.
GAAP EPS includes the “catch-up” stock-based compensation expense referred to above.
For more details about Axon’s innovative stock-based compensation plans, which were approved by shareholders and align the interests of management and employees with shareholders, please see our online FAQ.
Quarterly Adjusted EBITDA was a record $38 million, representing 22% margin on revenue, and 48% incremental contribution margin. For the full year, adjusted EBITDA grew 43% to $88 million.
Cash and investments grew $43 million sequentially to approximately $396 million. Axon’s strong balance sheet, with zero debt, provides us with the latitude to continue growing our subscription contracts as a percentage of revenue.

Financial commentary by segment:

TASER:
 
THREE MONTHS ENDED
 
CHANGE
 
31 DEC 2019
 
30 SEP 2019
 
31 DEC 2018
 
QoQ
 
YoY
 
(in thousands)
 
 
 
 
Net sales
$
83,955

 
$
71,743

 
$
65,301

 
17.0
%
 
28.6
%
Gross margin
60.5
%
 
63.1
%
 
65.0
%
 
-260bp

 
-450bp


TASER revenue of $84 million grew 29% year over year, reflecting strong momentum in TASER 7, which began shipping in Q4 2018, and strong cartridge shipments in the quarter, reflecting our ability to meet a substantial demand backlog.
TASER gross margin declined, as expected, due to the mix of TASER 7 cartridges shipped in the quarter. We anticipate that segment gross margin will improve in 2020, building throughout the year, driven by product mix, continued TASER 7 program cost optimization and a reduction in discounts.






Software & Sensors:
 
THREE MONTHS ENDED
 
CHANGE
 
31 DEC 2019
 
30 SEP 2019
 
31 DEC 2018
 
QoQ
 
YoY
 
(in thousands)
 
 
 
 
Axon Cloud net sales
$
36,805

 
$
34,021

 
$
25,774

 
8.2
%
 
42.8
%
Axon Cloud gross margin
76.1
%
 
75.8
%
 
74.5
%
 
30bp

 
160bp

 
 
 
 
 
 
 
 
 
 
Sensors and Other net sales
$
51,091

 
$
25,073

 
$
23,716

 
103.8
%
 
115.4
%
Sensors and Other gross margin
27.0
%
 
36.4
%
 
15.7
%
 
-940bp

 
1,130bp


Axon Cloud revenue grew 43% and achieved gross margins of 76.1% in Q4 2019. This margin includes some low-to-no-margin professional services that support new installations for SaaS customers. The software-only revenue in this segment, which includes cloud storage and compute costs, has consistently carried a gross margin above 80%.
Strong revenue in the Sensors and Other category was driven by record body camera shipments of about 83,000 units, topping the previous record of nearly 29,000 units shipped in Q3 2017. (These unit figures exclude the Axon Flex line-of-sight camera, which affixes to an officer’s sunglasses or hat brim.) Approximately 75% of Q4 2019 body camera unit shipments were Axon Body 3. We expect a significantly lower run-rate of body camera unit sales going forward.
Sensors and Other gross margin of 27% was in line with our expectations. As a reminder, we manage toward a 25% gross margin for camera and sensors hardware, and the gross margin will fluctuate quarter to quarter depending on the customer mix.

Forward-Looking Performance Indicators:
 
31 DEC 2019
 
30 SEP 2019
 
30 JUN 2019
 
31 MAR 2019
 
31 DEC 2018
 
($ in thousands)
Annual recurring revenue (1)
$
161,277

 
$
141,540

 
$
129,452

 
$
122,276

 
$
108,496

Total company future contracted revenue
$
1,230,000

 
$
1,130,000

 
$
1,050,000

 
$
930,000

 
$
900,000

Percentage of TASER devices sold on a recurring payment plan
58
%
 
55
%
 
60
%
 
42
%
 
35
%
(1) Monthly recurring license, integration, warranty, and storage revenue annualized.

Annual recurring revenue grew 49% year over year to $161 million, driven by strong adoption of our integrated software-heavy bundles and features.
Total company future contracted revenue grew to $1.23 billion. This amount is limited to revenue from arrangements that meet the definition of a contract under Topic 606 as of December 31, 2019. We expect to recognize between 20% to 25% of this balance over the next 12 months and generally expect the remainder to be recognized over the following five to seven years, subject to risks related to delayed deployments, budget appropriation or other contract cancellation clauses.
We have substantially moved the needle on driving TASER subscriptions in the past year. Approximately 58% of all devices sold in Q4 were on a recurring payment plan, compared with 35% a year ago. In the United States, recurring payment plans accounted for 65% of new TASER contracts, with TASER 7 contracts driving subscriptions. This represents significant progress toward transitioning the TASER business to a subscription model.





Record quarterly software and sensors bookings of $171 million were up 55% year over year. Going forward, we will not be disclosing this metric. It was introduced in the early days of our Software & Sensors business, and is no longer strategically relevant to evaluating the health of the segment. We believe that total company future contracted revenue is a more relevant and comprehensive forward-looking performance indicator, as it encompasses all company contracts, including TASER.
We ended the year with 465,200 users on the Axon network. Going forward, we are retiring this metric, which is declining in relevance as our business continues to evolve. We believe that annual recurring revenue provides a more useful measure of the health of the SaaS business we are building.

Outlook:

For the full year 2020, we expect to achieve:
Revenue in the range of $615 million to $625 million;
At the midpoint, this represents 17% year-over-year growth, and more than 20% year-over-year growth excluding the surge of Axon Body 3 hardware shipments in Q4 2019;
We anticipate that Q1 2020 revenue will increase approximately 13% year-over-year;
We anticipate that 2020 revenue will accelerate in the second half of the year, with a back-half weighting similar to 2019;
Adjusted EBITDA in the range of $100 million to $105 million;
Adjusted EBITDA guidance reflects modest gross margin improvement over 2019, which will be partially offset by camera hardware shipments to major city customers;
Adjusted EBITDA guidance reflects accelerated investments to take advantage of total addressable market expansion opportunities in new product categories, such as communications, and new customer categories, such as federal and corrections, as described above, and in building out systems for scale;
Adjusted EBITDA guidance excludes expected legal costs of up to $15 million associated with litigation involving the FTC, which we intend to treat as an add-back to Adjusted EBITDA;
We expect Adjusted EBITDA margin of approximately 10% to 12% in Q1 2020;
We expect a normalized tax rate of 20% to 25%, which can fluctuate depending on geography of income and the effects of discrete items, including changes in our stock price;
We expect stock-based compensation expenses to be approximately $85 million for the full year, which is subject to change depending on our assessment of the probability of attaining operational metrics for the CEO Performance Award and XSPP awards, and the expected timing of such attainment; and
We are closely monitoring our supply chain and operations in the context of the coronavirus crisis. Though the situation is dynamic, at this time, we believe the potential impact to Axon is reflected in our full-year guidance.

This is an exciting time for Axon and its customers -- the products we are bringing to market are fundamentally improving public safety, creating massive societal value, and saving lives. Thank you for joining us on this journey.

Signed,
Rick Smith, CEO
Luke Larson, President
Jawad Ahsan, CFO









Quarterly conference call and Webcast

We will host our Q4 2019 earnings conference call on February 27 at 2 p.m. PT / 5 p.m. ET.

The call will be available via live audio webcast and archived replay on Axon's investor relations website at https://investor.axon.com.

Statistical Definitions

Software and Sensors bookings are an indication of the activity the Company is seeing relative to Software and Sensors hardware, software and Axon Evidence. We consider bookings to be a statistical measure defined as the sales price of orders (not invoiced sales), including contractual optional periods we expect to be exercised, net of cancellations, inclusive of renewals, placed in the relevant fiscal period, regardless of when the products or services ultimately will be provided. Most bookings will be invoiced in subsequent periods.

Due to municipal government funding rules, in some cases certain of the future period amounts included in bookings are subject to budget appropriation or other contract cancellation clauses. Although Axon has entered into contracts for the delivery of products and services in the future and anticipates the contracts will be fulfilled, if agencies do not exercise contractual options, do not appropriate money in future year budgets or do enact a cancellation clause, revenue associated with these bookings may not ultimately be recognized, resulting in a future reduction to bookings.

For more information relative to our revenue recognition policies, please reference our SEC filings.

Non-GAAP Measures

To supplement the Company's financial results presented in accordance with GAAP, we present the non-GAAP financial measures of EBITDA, Adjusted EBITDA, Non-GAAP Net Income, Non-GAAP Diluted Earnings Per Share and Free Cash Flow. The Company's management uses these non-GAAP financial measures in evaluating the Company's performance in comparison to prior periods. We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing its performance, and when planning and forecasting our future periods. A reconciliation of GAAP to the non-GAAP financial measures is presented herein.

EBITDA (Most comparable GAAP Measure: Net income) - Earnings before interest expense, investment interest income, income taxes, depreciation and amortization.
Adjusted EBITDA (Most comparable GAAP Measure: Net income) - Earnings before interest expense, investment interest income, income taxes, depreciation, amortization, non-cash stock-based compensation expense and pre-tax certain other items (described below).
Non-GAAP Net Income (Most comparable GAAP Measure: Net income) - Net income excluding the costs of non-cash stock-based compensation and excluding pre-tax certain other items, including, but not limited to, net gain/loss/write-down/disposal/abandonment of property, equipment and intangible assets; loss on impairment; and costs related to business acquisitions. The Company tax-effects non-GAAP adjustments using the blended statutory federal and state tax rates for each period presented.
Non-GAAP Diluted Earnings Per Share (Most comparable GAAP Measure: Earnings Per share) - Measure of Company's Non-GAAP Net Income divided by the weighted average number of diluted common shares outstanding during the period presented.





Free Cash Flow (Most comparable GAAP Measure: Cash flow from operating activities) - cash flows provided by operating activities minus purchases of property and equipment, intangible assets and cash flows related to business acquisitions.

Caution on Use of Non-GAAP Measures

Although these non-GAAP financial measures are not consistent with GAAP, management believes investors will benefit by referring to these non-GAAP financial measures when assessing the Company's operating results, as well as when forecasting and analyzing future periods. However, management recognizes that:

these non-GAAP financial measures are limited in their usefulness and should be considered only as a supplement to the Company's GAAP financial measures;
these non-GAAP financial measures should not be considered in isolation from, or as a substitute for, the Company's GAAP financial measures;
these non-GAAP financial measures should not be considered to be superior to the Company's GAAP financial measures; and
these non-GAAP financial measures were not prepared in accordance with GAAP or under a comprehensive set of rules or principles.

Further, these non-GAAP financial measures may be unique to the Company, as they may be different from similarly titled non-GAAP financial measures used by other companies. As such, this presentation of non-GAAP financial measures may not enhance the comparability of the Company's results to the results of other companies.

About Axon

Axon is a network of devices, apps and people that helps public safety personnel become smarter and safer. With a mission of protecting life, our technologies give customers the confidence, focus and time they need to keep their communities safe. Our products impact every aspect of a public safety officer's day-to-day experience.

We work hard for those who put themselves in harm's way for all of us. More than 225,000 lives and countless dollars have been saved with the Axon network of devices, apps and people. Learn more at www.axon.com or by calling (800) 978-2737. Facebook is a trademark of Facebook, Inc.;LTE isa trademark of the European Telecommunications Standards Institute; Oculus is a trademark of Facebook Technologies, LLC;Twitter is a trademark of Twitter, Inc. and Zoom is a trademark of Zoom Video Communications, Inc.

Axon, Axon Records, Axon Dispatch, Axon Performance, Axon Standards, Axon Body, Redaction Assistant, Axon Accelerate, Axon Evidence, Axon Academy,Axon Fleet, TASER, TASER 7 and the Delta Logo are trademarks of Axon Enterprise, Inc., some of which are registered in the US and other countries. For more information, visit www.axon.com/legal. All rights reserved.

Follow Axon here:
Axon on Twitter: https://twitter.com/axon_us
Axon on Facebook: https://www.facebook.com/Axon.ProtectLife/

Forward-looking statements

These forward-looking statements include, without limitation, statements regarding: proposed products and services and related development efforts and activities; expectations about the market for our current and





future products and services; expectations about customer behavior; statements concerning projections, predictions, expectations, estimates or forecasts as to our business, financial and operational results and future economic performance; and statements of management’s strategies, goals and objectives and other similar expressions; as well as the ultimate resolution of financial statement items requiring critical accounting estimates, including those set forth in our Form 10-K for the year ended December 31, 2019. Such statements give our current expectations or forecasts of future events; they do not relate strictly to historical or current facts. Words such as “may,” “will,” “should,” “could,” “would,” “predict,” “potential,” “continue,” “expect,” “anticipate,” “future,” “intend,” “plan,” “believe,” “estimate,” and similar expressions, as well as statements in future tense, identify forward-looking statements. However, not all forward-looking statements contain these identifying words.

We cannot guarantee that any forward-looking statement will be realized, although we believe we have been prudent in our plans and assumptions. Achievement of future results is subject to risks, uncertainties and potentially inaccurate assumptions.The following important factors could cause actual results to differ materially from those in the forward-looking statements: our ability to design, introduce and sell new products or features; our ability to defend against litigation and protect our intellectual property, and the resulting costs of this activity; our ability to manage our supply chain and avoid production delays, shortages, and impacts to expected gross margins; the impact of stock compensation expense, impairment expense, and income tax expense on our financial results; customer purchase behavior, including adoption of our software as a service delivery model; our exposure to cancellations of government contracts due to appropriation clauses, exercise of a cancellation clause, or non-exercise of contractually optional periods; negative media publicity regarding our products; the impact of product mix on projected gross margins; defects in our products; changes in the costs of product components and labor; loss of customer data, a breach of security, or an extended outage, including our reliance on third party cloud-based storage providers; exposure to international operational risks; delayed cash collections and possible credit losses due to our subscription model; changes in government regulations in the U.S. and in foreign markets, especially related to the classification of our product by the United States Bureau of Alcohol, Tobacco, Firearms and Explosives and to evolving regulations surrounding privacy and data protection; our ability to integrate acquired businesses; our ability to attract and retain key personnel; and counter-party risks relating to cash balances held in excess of FDIC insurance limits.Many events beyond our control may determine whether results we anticipate will be achieved. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected. You should bear this in mind as you consider forward-looking statements. Our Annual Report on Form 10-K lists various important factors that could cause actual results to differ materially from expected and historical results. These factors are intended as cautionary statements for investors within the meaning of Section 21E of the Exchange Act and Section 27A of the Securities Act. Readers can find them under the heading "Risk Factors" in the Annual Report on Form 10-K and in the Quarterly Report on Form 10-Q, and investors should refer to them. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider any such list to be a complete set of all potential risks or uncertainties.

Except as required by law, we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our Form 10-Q, 8-K and 10-K reports to the SEC.

Please visit https://investor.axon.com, https://www.axon.com/press, www.twitter.com/axon_us and https://www.facebook.com/Axon.ProtectLife/ where Axon discloses information about the company, its financial information, and its business.

For investor relations information please contact Andrea James via email at IR@axon.com.








AXON ENTERPRISE, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(in thousands, except per share data)

 
THREE MONTHS ENDED
 
TWELVE MONTHS ENDED
 
31 DEC 2019
 
30 SEP 2019
 
31 DEC 2018
 
31 DEC 2019
 
31 DEC 2018
Net sales from products
$
134,497


$
96,497


$
89,017

 
$
399,474

 
$
327,635

Net sales from services
37,354


34,340


25,774

 
131,386

 
92,433

Net sales
171,851


130,837


114,791

 
530,860

 
420,068

Cost of product sales
70,418


42,445


42,863

 
190,683

 
139,337

Cost of service sales
8,793


8,223


6,582

 
32,891

 
22,148

Cost of sales
79,211


50,668


49,445

 
223,574

 
161,485

Gross margin
92,640


80,169


65,346

 
307,286

 
258,583

Operating expenses:
 




 

 
 
Sales, general and administrative
78,281


48,424


42,099

 
212,959

 
156,886

Research and development
28,745


25,129


21,254

 
100,721

 
76,856

Total operating expenses
107,026


73,553


63,353

 
313,680

 
233,742

Income (loss) from operations
(14,386
)

6,616


1,993

 
(6,394
)
 
24,841

Interest and other income, net
2,486


1,820


1,021

 
8,464

 
3,263

Income (loss) before provision for income taxes
(11,900
)

8,436


3,014

 
2,070

 
28,104

Provision for (benefit from) income taxes
479


2,332


931

 
1,188

 
(1,101
)
Net income (loss)
$
(12,379
)

$
6,104


$
2,083

 
$
882

 
$
29,205

Net income (loss) per common and common equivalent shares:





 

 
 
Basic
$
(0.21
)

$
0.10


$
0.04

 
$
0.01

 
$
0.52

Diluted
$
(0.21
)

$
0.10


$
0.03

 
$
0.01

 
$
0.50

Weighted average number of common and common equivalent shares outstanding:





 

 
 
Basic
59,374


59,278


58,502

 
59,190

 
56,392

Diluted
60,257


60,059


59,665

 
60,018

 
57,922







AXON ENTERPRISE, INC.
SEGMENT REPORTING
(Unaudited)
(dollars in thousands)

 
THREE MONTHS ENDED
31 DEC 2019
 
THREE MONTHS ENDED
30 SEP 2019
 
THREE MONTHS ENDED
31 DEC 2018
 
TASER
 
Software and Sensors
 
Total
 
TASER
 
Software and Sensors
 
Total
 
TASER
 
Software and Sensors
 
Total
Net sales from products (1)
$
83,406

 
$
51,091

 
$
134,497

 
$
71,424

 
$
25,073

 
$
96,497

 
$
65,301

 
$
23,716

 
$
89,017

Net sales from services (2)
549

 
36,805

 
37,354

 
319

 
34,021

 
34,340

 

 
25,774

 
25,774

Net sales
83,955

 
87,896

 
171,851

 
71,743

 
59,094

 
130,837

 
65,301

 
49,490

 
114,791

Cost of product sales
33,144

 
37,274

 
70,418

 
26,504

 
15,941

 
42,445

 
22,874

 
19,989

 
42,863

Cost of service sales

 
8,793

 
8,793

 

 
8,223

 
8,223

 

 
6,582

 
6,582

Cost of sales
33,144

 
46,067

 
79,211

 
26,504

 
24,164

 
50,668

 
22,874

 
26,571

 
49,445

Gross margin
50,811

 
41,829

 
92,640

 
45,239

 
34,930

 
80,169

 
42,427

 
22,919

 
65,346

Gross margin %
60.5
%
 
47.6
%
 
53.9
%
 
63.1
%
 
59.1
%
 
61.3
%
 
65.0
%
 
46.3
%
 
56.9
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research and development
4,185

 
24,560

 
28,745

 
3,485

 
21,644

 
25,129

 
5,196

 
16,058

 
21,254



 
TWELVE MONTHS ENDED
31 DEC 2019
 
TWELVE MONTHS ENDED
31 DEC 2018
 
TASER
 
Software and Sensors
 
Total
 
TASER
 
Software and Sensors
 
Total
Net sales from products (1)
$
280,554


$
118,920


$
399,474


$
253,115


$
74,520


$
327,635

Net sales from services (2)
1,107


130,279


131,386




92,433


92,433

Net sales
281,661


249,199


530,860


253,115


166,953


420,068

Cost of product sales
107,188


83,495


190,683


80,354


58,983


139,337

Cost of service sales


32,891


32,891




22,148


22,148

Cost of sales
107,188


116,386


223,574


80,354


81,131


161,485

Gross margin
174,473


132,813


307,286


172,761


85,822


258,583

Gross margin %
61.9
%
 
53.3
%
 
57.9
%
 
68.3
%
 
51.4
%
 
61.5
%
 
 
 
 
 
 
 
 
 
 
 
 
Research and development
14,469


86,252


100,721


17,012


59,844


76,856


(1) Software and Sensors “products” revenue consists of sensors, including on-officer body cameras, Axon Fleet cameras, other hardware sensors, warranties on sensors, and other products, and is sometimes referred to as Sensors and Other revenue.

(2) Software and Sensors “services” revenue comprises sales related to the Axon Cloud, which includes Axon Evidence, cloud-based evidence management software revenue, other recurring cloud-hosted software revenue and related professional services, and is sometimes referred to as Axon Cloud revenue.






AXON ENTERPRISE, INC.
UNIT SALES STATISTICS
(Unaudited)
Units in whole numbers

 
THREE MONTHS ENDED
 
TWELVE MONTHS ENDED 31 DEC
 
31 DEC 2019
 
31 DEC 2018
 
Unit Change
 
Percent Change
 
31 DEC 2019
 
31 DEC 2018
 
Unit Change
 
Percent Change
TASER 7
14,577

 
5,759

 
8,818

 
153.1
 %
 
49,221

 
5,759

 
43,462

 
754.7
 %
TASER X26P
13,554

 
18,597

 
(5,043
)
 
(27.1
)
 
48,798

 
71,823

 
(23,025
)
 
(32.1
)
TASER X2
11,534

 
13,088

 
(1,554
)
 
(11.9
)
 
40,973

 
65,855

 
(24,882
)
 
(37.8
)
TASER Pulse and Bolt
2,978

 
7,490

 
(4,512
)
 
(60.2
)
 
11,785

 
18,398

 
(6,613
)
 
(35.9
)
Cartridges
962,519

 
600,690

 
361,829

 
60.2

 
2,751,603

 
2,342,897

 
408,706

 
17.4

Axon Body
83,268

 
26,167

 
57,101

 
218.2

 
151,499

 
85,965

 
65,534

 
76.2

Axon Flex
3,078

 
5,080

 
(2,002
)
 
(39.4
)
 
15,586

 
15,541

 
45

 
0.3

Axon Fleet
3,324

 
3,908

 
(584
)
 
(14.9
)
 
10,467

 
9,445

 
1,022

 
10.8

Axon Dock
10,149

 
3,859

 
6,290

 
163.0

 
22,275

 
17,762

 
4,513

 
25.4

TASER Cam
1,177

 
1,952

 
(775
)
 
(39.7
)
 
5,533

 
8,310

 
(2,777
)
 
(33.4
)









AXON ENTERPRISE, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(Unaudited)
Dollars in thousands

 
THREE MONTHS ENDED
 
TWELVE MONTHS ENDED
 
31 DEC 2019
 
30 SEP 2019
 
31 DEC 2018
 
31 DEC 2019
 
31 DEC 2018
EBITDA and Adjusted EBITDA:









Net income (loss)
$
(12,379
)

$
6,104


$
2,083


$
882


$
29,205

Depreciation and amortization
3,165


2,709


2,389


11,361


10,615

Interest expense
19


4


33


46


86

Investment interest income
(1,760
)

(1,647
)

(1,076
)

(7,040
)

(3,002
)
Provision for (benefit from) income taxes
479


2,332


931


1,188


(1,101
)
EBITDA
$
(10,476
)

$
9,502


$
4,360


$
6,437


$
35,803

 









Adjustments:









Stock-based compensation expense
$
48,300


$
13,663


$
6,577


$
78,495


$
21,879

Transaction costs and adjustments related to business acquisition








1,382

Loss on disposal and abandonment of intangible assets
16


33


14


67


2,117

Loss on disposal and impairment of property and equipment, net
134


845


13


2,542


303

Costs related to FTC litigation
240

 

 

 
240

 

Adjusted EBITDA
$
38,214


$
24,043


$
10,964


$
87,781


$
61,484

Net income (loss) as a percentage of net sales
(7.2
)%

4.7
%

1.8
%

0.2
%

7.0
%
Adjusted EBITDA as a percentage of net sales
22.2
 %

18.4
%

9.6
%

16.5
%

14.6
%
 
 
 
 
 
 
 
 
 
 
Stock-based compensation expense:
 
 
 
 
 
 
 
 
 
Cost of product and service sales
$
790

 
$
312

 
$
152

 
$
1,565

 
$
511

Sales, general and administrative
40,212

 
9,508

 
3,927

 
59,342

 
12,710

Research and development
7,298

 
3,843

 
2,498

 
17,588

 
8,658

Total
$
48,300

 
$
13,663

 
$
6,577

 
$
78,495

 
$
21,879











AXON ENTERPRISE, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES - continued
(Unaudited)
Dollars in thousands
 
THREE MONTHS ENDED
 
TWELVE MONTHS ENDED
 
31 DEC 2019
 
30 SEP 2019
 
31 DEC 2018
 
31 DEC 2019
 
31 DEC 2018
Non-GAAP net income:









GAAP net income (loss)
$
(12,379
)

$
6,104


$
2,083


$
882


$
29,205

Non-GAAP adjustments:












Stock-based compensation expense
48,300


13,663


6,577


78,495


21,879

Loss on disposal and abandonment of intangible assets
16


33


14


67


2,117

Loss on disposal and impairment of property and equipment, net
134


845


13


2,542


303

Transaction costs and adjustments related to business acquisition








1,382

Costs related to FTC litigation
240






240



Income tax effects
(11,863
)

(3,654
)

(1,737
)

(20,068
)

(6,366
)
Income tax benefit of CEO stock option exercise




(2,321
)



(5,683
)
Non-GAAP net income
$
24,448


$
16,991


$
4,629


$
62,158


$
42,837


 
THREE MONTHS ENDED
 
TWELVE MONTHS ENDED
 
31 DEC 2019
 
30 SEP 2019
 
31 DEC 2018
 
31 DEC 2019
 
31 DEC 2018
Non-GAAP diluted earnings per share:









GAAP diluted earnings per share
$
(0.21
)

$
0.10


$
0.03


$
0.01


$
0.50

Non-GAAP adjustments:












Stock-based compensation expense
0.80


0.23


0.11


1.31


0.38

Loss on disposal and abandonment of intangible assets
0.00


0.00


0.00


0.00


0.04

Loss on disposal and impairment of property and equipment, net
0.00


0.01


0.00


0.04


0.01

Transaction costs and adjustments related to business acquisition








0.02

Costs related to FTC litigation
0.00






0.00



Income tax effects
(0.20
)

(0.06
)

(0.03
)

(0.33
)

(0.11
)
Income tax benefit of CEO stock option exercise




(0.04
)



(0.10
)
Non-GAAP diluted earnings per share (1)
$
0.41


$
0.28


$
0.08


$
1.04


$
0.74

 









Weighted average number of diluted common and common equivalent shares outstanding (in thousands)
60,257


60,059


59,665


60,018


57,922

(1) The per share calculations for GAAP net income, Non-GAAP adjustments and Non-GAAP diluted earnings per share are each computed independently. Per share amounts may not sum due to rounding.




AXON ENTERPRISE, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands)
 
31 DEC 2019
 
31 DEC 2018
 
(Unaudited)
 
 
ASSETS
Current Assets:

 

Cash and cash equivalents
$
172,250

 
$
349,462

Short-term investments
178,534

 

Accounts and notes receivable, net
146,878

 
130,579

Contract assets, net
47,718

 
13,960

Inventory, net
38,845

 
33,763

Prepaid expenses and other current assets
34,866

 
30,391

Total current assets
619,091

 
558,155




 

Property and equipment, net
43,770

 
37,893

Deferred tax assets, net
27,688

 
19,347

Intangible assets, net
12,771

 
15,935

Goodwill
25,013

 
24,981

Long-term investments
45,499

 

Long-term notes receivable, net of current portion
31,598

 
40,230

Other assets
40,209

 
22,999

Total assets
$
845,639

 
$
719,540


LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:


 


Accounts payable
25,874

 
15,164

Accrued liabilities
45,001

 
41,092

Current portion of deferred revenue
117,864

 
107,016

Customer deposits
2,974

 
2,702

Other current liabilities
3,853

 
37

Total current liabilities
195,566

 
166,011




 


Deferred revenue, net of current portion
87,936

 
74,417

Liability for unrecognized tax benefits
3,832

 
2,849

Long-term deferred compensation
3,936

 
3,235

Deferred tax liability
354

 

Other long-term liabilities
10,520

 
5,704

Total liabilities
302,144

 
252,216




 


Stockholders’ Equity:


 


Preferred stock

 

Common stock
1

 
1

Additional paid-in capital
528,272

 
453,400

Treasury stock
(155,947
)
 
(155,947
)
Retained earnings
172,265

 
171,383

Accumulated other comprehensive loss
(1,096
)
 
(1,513
)
Total stockholders’ equity
543,495

 
467,324

Total liabilities and stockholders’ equity
$
845,639

 
$
719,540







AXON ENTERPRISE, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
 
THREE MONTHS ENDED
 
TWELVE MONTHS ENDED
 
31 DEC 2019
 
30 SEP 2019
 
31 DEC 2018
 
31 DEC 2019
 
31 DEC 2018
Cash flows from operating activities:
 
 
 
 
 
 
 
 
 
Net income (loss)
$
(12,379
)
 
$
6,104

 
$
2,083

 
$
882

 
$
29,205

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
 
 
 
 
 
 
Depreciation and amortization
3,165


2,709


2,389


11,361


10,615

Loss on disposal and abandonment of intangible assets
16


33


14


67


2,117

Loss (gain) on disposal and impairment of property and equipment, net
134


845


13


2,542


303

Stock-based compensation
48,300


13,663


6,577


78,495


21,879

Deferred income taxes
(4,041
)

(2,635
)

(1,266
)

(7,987
)

(3,592
)
Unrecognized tax benefits
389


(19
)

1,045


983


1,144

Other noncash, net
1,005


1,101




3,928


34

Change in assets and liabilities:
 
 
 
 
 
 
 
 
 
Accounts and notes receivable and contract assets
(8,333
)
 
(19,491
)
 
(16,471
)
 
(38,830
)
 
(67,643
)
Inventory
1,399

 
1,213

 
5,771

 
(4,903
)
 
14,804

Prepaid expenses and other assets
2,122

 
(6,206
)
 
(658
)
 
(9,845
)
 
(12,739
)
Accounts payable, accrued liabilities and other liabilities
18,495

 
3,224

 
9,200

 
4,967

 
13,506

Deferred revenue
(4,463
)
 
21,899

 
22,542

 
24,013

 
54,242

Net cash provided by operating activities
45,809

 
22,440

 
31,239

 
65,673

 
63,875

Cash flows from investing activities:
 
 
 
 
 
 
 
 
 
Purchases of investments
(111,784
)

(100,701
)



(354,477
)

(4,331
)
Proceeds from call / maturity of investments
37,876


66,888


500


130,083


11,158

Purchases of property and equipment
(3,828
)

(4,250
)

(4,259
)

(15,939
)

(11,139
)
Purchases of intangible assets
(76
)

16


(98
)

(404
)

(558
)
Business acquisitions, net of cash acquired








(4,990
)
Net cash used in investing activities
(77,812
)

(38,047
)

(3,857
)

(240,737
)

(9,860
)
Cash flows from financing activities:
 
 
 
 
 
 
 
 
 
Net proceeds from equity offering








233,993

Proceeds from options exercised
8


2


1,044


114


1,757

Income and payroll tax payments for net-settled stock awards
(783
)

(1,136
)

(2,154
)

(4,051
)

(14,127
)
Payment of contingent consideration for business acquisitions




(1,700
)



(2,275
)
Net cash provided by (used in) financing activities
(775
)

(1,134
)

(2,810
)

(3,937
)

219,348

Effect of exchange rate changes on cash and cash equivalents
1,007


(426
)

(393
)

329


(774
)
Net increase (decrease) in cash and cash equivalents and restricted cash
(31,771
)

(17,167
)

24,179


(178,672
)

272,589

Cash and cash equivalents, beginning of period
204,126


221,293


326,848


351,027


78,438

Cash and cash equivalents, end of period
$
172,355


$
204,126


$
351,027


$
172,355


$
351,027

 






AXON ENTERPRISE, INC.
SELECTED CASH FLOW INFORMATION
(Unaudited)
(in thousands)


 
THREE MONTHS ENDED
 
TWELVE MONTHS ENDED
 
31 DEC 2019
 
30 SEP 2019
 
31 DEC 2018
 
31 DEC 2019
 
31 DEC 2018
 
 
 
 
 
 
 
 
 
 
Net cash provided by operating activities
$
45,809

 
$
22,440

 
$
31,239

 
$
65,673

 
$
63,875

Purchases of property and equipment
(3,828
)
 
(4,250
)
 
(4,259
)
 
(15,939
)
 
(11,139
)
Purchases of intangible assets
(76
)
 
16

 
(98
)
 
(404
)
 
(558
)
Cash flows related to business acquisitions

 

 

 

 
(4,990
)
Free cash flow, a non-GAAP measure
$
41,905

 
$
18,206

 
$
26,882

 
$
49,330

 
$
47,188











AXON ENTERPRISE, INC.
SUPPLEMENTAL TABLES
(in thousands)

 
31 DEC 2019
 
31 DEC 2018
 
(Unaudited)
 
 
Cash and cash equivalents
$
172,250

 
$
349,462

Short-term investments
178,534

 

Long-term investments
45,499

 

Total cash and cash equivalents and investments
$
396,283

 
$
349,462